<DOC>
	<DOCNO>NCT01768845</DOCNO>
	<brief_summary>Hematopoietic progenitor cell ( HPC- primitive cell blood , bone marrow umbilical cord restore bone marrow ) transplant curative therapy treatment hematologic malignancy ( disease bone marrow lymph node ) . The source cell use transplant come relate ( sibling ) case sibling match , unrelated donor National Marrow Donor Program . The availability suitable donor significant obstacle patient need transplant match donor . Cord blood harvest umbilical cord shortly birth rich supply cell need transplant . These store cord blood use transplant adult without match donor Advantages use cord blood include readily available source cell risk donor collection process , immediate source cell urgent situation ( lengthy donor work-up ) reduction infectious disease transmission recipient . One main disadvantage cord blood small number cell need transplant . In adult , usually two cord need large recipient qualify need many cell . This study use two different preparative regimen ( chemotherapy radiation ) follow one two umbilical cord unit ( UBC ) . The preparative regimen use chosen physician base patient 's age , disease medical condition time transplant . Multiple objectives study include disease-free overall survival , treatment related mortality , rate cell take hold , incidence severity transplant complication call graft versus host disease ( GVHD ) .</brief_summary>
	<brief_title>Unrelated Umbilical Cord Blood ( UBC ) Transplantation</brief_title>
	<detailed_description>Allogeneic hematopoietic cell transplantation ( allo- HCT ) curative therapy treatment hematological non-hematological malignancy certain non-malignant condition . Bone marrow peripheral blood Human Leukocyte Antigen ( HLA ) match sibling donor commonly use source allogeneic stem cell . However , HLA match sibling available less one third patient require allo- SCT . In absence HLA match sibling , volunteer unrelated donor partially mismatch related donor ( PMRD ) , store cord blood may use source allogeneic stem cell . Stored cord blood use source allogeneic stem cell infants child , early skepticism adult concern engraftment potential relatively limited number stem cell . The number stem cell unit cord blood generally one log less number stem cell average collection bone marrow adult transplantation . After success first allogeneic umbilical cord blood transplantation 1988 , program bank screen unrelated donor CBSC initiate United States Europe . Dr Pablo Rubenstein start first bank New York Blood Center ( NYBC ) 1993 . Since inception , NYBC provide unrelated donor cord blood stem cell 1000 transplant . Analysis outcomes initial 562 transplant recipient NYBC reveal cumulative rate engraftment 81 % day 42 PMNs . 85 % day 180 platelet . Currently , approximately 100,000 cord blood unit available cord blood bank worldwide 2000 patient receive cord blood transplant bank . NetCord , international cooperative group cord blood bank , develop detailed set standard cord blood banking facilitate international exchange guarantee quality product . Cord Blood Unit Selection : UCB unit require 4 6 6 HLA-A , -B antigen -DRB1 allele match patient . Typing HLA-C -DQ obtain required match strategy . A minimum total nucleate cell ( TNC ) dose &gt; 2.0 x 107/kg time freeze utilized possible . When use double unit , unit contain minimum pre-cryopreserved TNC dose 1.5 x 107/kg . UCB Transplant Procedure : There myeloablative reduced-intensity preparative regimen give prior infusion cord product . The myeloablative approach select young patient ( &lt; 50yo ) HCT-CI score &lt; 3 . The reduced-intensity regimen select old patient ( &gt; 50 ) young patient HCT-CI score &gt; 3 . The reduced-intensity regimen also choose patient transplant indolent/follicular lymphoma , CLL , myeloma , Hodgkin lymphoma ; irrelevant age HCT-CI score . On case case basis , patient may receive preparative regimen outside designated category note approval PI , deem patient 's best interest .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Age : 1670 year Available 4/6 , 5/6 , 6/6 HLA antigen match ( use A , B , DRB1 ) cord blood unit . ECOG performance status 02 ( Karnofsky great equal 70 % ) Serum bilirubin le 2 x upper limit normal Serum creatinine le 2 mg/dl DLCO FEV1 great equal 50 % predict Left ventricular ejection fraction great equal 35 % uncontrolled infection If female , pregnant Informed consent give No major organ dysfunction preclude transplantation . One follow malignancy bone marrow failure syndrome : Chronic myelogenous leukemia ( CML ) Acute myelogenous leukemia ( AML ) Myelodysplastic syndrome Multiple myeloma Hodgkin lymphoma NonHodgkin lymphoma Chronic lymphocytic leukemia ( CLL ) Acute lymphocytic leukemia ( ALL ) Severe Aplastic Anemia Patient pregnant Age le 16 , great 70 ECOG performance status great 2 ( Karnofsky less 70 % ) Psychiatric disorder mental deficiency patient sufficiently severe make compliance BMT treatment unlikely , make informed consent impossible Serum bilirubin great equal 2 x upper limit normal , transaminases great 3 x upper limit normal Serum creatinine great equal 2 mg/dl DLCO le 50 % predict Left ventricular ejection fraction le 35 % Major anticipated illness organ failure incompatible survival BMT</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic myelogenous leukemia ( CML )</keyword>
	<keyword>Acute myelogenous leukemia ( AML )</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>Hodgkin lymphoma</keyword>
	<keyword>Non Hodgkin lymphoma</keyword>
	<keyword>Chronic lymphocytic leukemia ( CLL )</keyword>
	<keyword>Acute lymphocytic leukemia ( ALL )</keyword>
	<keyword>Severe Aplastic Anemia</keyword>
	<keyword>Cord Blood</keyword>
	<keyword>Umbilical cord blood transplantation</keyword>
	<keyword>UBC transplantation</keyword>
</DOC>